AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical firm pioneering precision drugs for neurodegenerative ailments, at this time introduced that it’ll host a KOL webinar on amyloid plaque PET imaging in Alzheimer’s Disease as a surrogate of medical efficacy on Thursday, November 9, 2023 at 10:00am ET / 4:00pm CET. To register, click here.
The occasion will function Prof. Victor Villemagne, MD (University of Pittsburgh), who will talk about the heightened curiosity in amyloid plaque PET imaging and the methodology, mechanisms, and medical implications of plaque decreasing in gentle of recent profitable trials.
The AC Immune workforce can even spotlight its anti-Abeta lively immunotherapy candidate, ACI-24.060, at present being evaluated within the ongoing Phase 1b/2 ABATE research for the therapy of Alzheimer’s illness. Initial amyloid-PET imaging analyses in Alzheimer’s sufferers to evaluate amyloid plaque discount after 6 months of therapy with ACI-24.060 within the ABATE trial are anticipated within the first half of 2024.
A stay query and reply session will comply with the shows.
About Prof. Victor Villemagne, MD
Prof. Victor Villemagne, MD graduated Cum Laude in 1983 from the Universidad Nacional de Buenos Aires, Argentina. He was awarded a Post-Doctoral Fellowship in Nuclear Medicine in 1984 and continued his post-graduate research on the Division of Nuclear Medicine at The Johns Hopkins Medical Institutions. He subsequently furthered his molecular neuroimaging coaching at NIDA (NIH), and on the University of Pittsburgh.
In 2003 he joined the Neurodegeneration group on the University of Melbourne, the place he carried out a number of preclinical and medical research of recent tracers for amyloid and tau imaging, and in 2020, he joined the Dept. of Psychiatry on the University of Pittsburgh. His analysis entails nationwide and worldwide collaborations with neuroscientists, chemists, molecular biologists, medical neurologists, molecular imaging specialists, and is commonly invited to current his analysis at worldwide conferences. With an h-index of 83, he has authored or co-authored a number of ebook chapters and requested critiques on molecular imaging, and greater than 440 unique analysis publications. Among different honors, he has obtained the de Leon Prize in Neuroimaging (Boston, USA, 2013), the Christopher Clark Award for the Continuing Advancement within the Field of Human Amyloid Imaging, (Miami, USA, 2014), and the Kuhl-Lassen award by the Society of Nuclear Medicine and Molecular Imaging (Philadelphia, USA, 2018). Since 2016 he has been acknowledged as one in every of The World’s Most Influential Scientific Minds based mostly on his citations being within the prime 1% on this planet within the subject of Neuroscience.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical firm that goals to turn into a worldwide chief in precision drugs for neurodegenerative ailments, together with Alzheimer’s illness, Parkinson’s illness, and NeuroOrphan indications pushed by misfolded proteins. The Company’s two clinically validated expertise platforms, SupraAntigen® and Morphomer®, gasoline its broad and diversified pipeline of first- and best-in-class property, which at present options sixteen therapeutic and diagnostic applications, 5 of that are at present in Phase 2 medical trials and one in every of which is in Phase 3. AC Immune has a robust observe file of securing strategic partnerships with main international pharmaceutical corporations together with Genentech, a member of the Roche Group, Eli Lilly and Company, and others, leading to substantial non-dilutive funding to advance its proprietary applications and >$3 billion in potential milestone funds.
SupraAntigen® is a registered trademark of AC Immune SA within the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The data on our web site and another web sites referenced herein is expressly not included by reference into, and doesn’t represent part of, this press launch.
For additional data, please contact:
Forward wanting statements
This press launch accommodates statements that represent “forward-looking statements” throughout the that means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements apart from historic reality and will embody statements that deal with future working, monetary or business efficiency or AC Immune’s methods or expectations. In some instances, you possibly can determine these statements by forward-looking phrases comparable to “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and different comparable terminology. Forward-looking statements are based mostly on administration’s present expectations and beliefs and contain vital dangers and uncertainties that would trigger precise outcomes, developments and business choices to vary materially from these contemplated by these statements. These dangers and uncertainties embody these described below the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and different filings with the Securities and Exchange Commission. Forward- wanting statements communicate solely as of the date they’re made, and AC Immune doesn’t undertake any obligation to update them in gentle of recent data, future developments or in any other case, besides as could also be required below relevant legislation. All forward-looking statements are certified of their entirety by this cautionary assertion.
Attachment
